Table 1 Imatinib-naive and... | American Society of Hematology

Table 1

Imatinib-naive and imatinib-treated CML-CP–like mice harbor leukemia clones expressing imatinib-resistant BCR-ABL1 kinase mutations

Mice*	Assay	Sensitivity	Detection†	Mutations
Untreated	D-HPLC	10⁻² to 10⁻³ (wt:mut mRNA)	0/7	—
Imatinib	D-HPLC	10⁻² to 10⁻³ (wt:mut mRNA)	0/5	—
Untreated	ASO-PCR	10⁻³ (wt:mut mRNA); 10⁻³ (cells)	1/7	E255K, T315I
Imatinib	ASO-PCR	10⁻³ (wt:mut mRNA); 10⁻³ (cells)	1/5	T315I
Untreated	Resistant colonies + sequencing	10⁻⁶ cells	5/7	E255K, T315I, H396P

Mice*	Assay	Sensitivity	Detection†	Mutations
Untreated	D-HPLC	10⁻² to 10⁻³ (wt:mut mRNA)	0/7	—
Imatinib	D-HPLC	10⁻² to 10⁻³ (wt:mut mRNA)	0/5	—
Untreated	ASO-PCR	10⁻³ (wt:mut mRNA); 10⁻³ (cells)	1/7	E255K, T315I
Imatinib	ASO-PCR	10⁻³ (wt:mut mRNA); 10⁻³ (cells)	1/5	T315I
Untreated	Resistant colonies + sequencing	10⁻⁶ cells	5/7	E255K, T315I, H396P

Leukemic mice were untreated or treated with imatinib as described in “Methods.”

Number of mice with mutations/total number of mice analyzed.